XML 73 R60.htm IDEA: XBRL DOCUMENT v3.22.2
Other intangible assets (Tables)
 12 Months Ended
Mar. 31, 2022
Disclosure of detailed information about intangible assets [abstract]  
Disclosure of detailed information about intangible assets explanatory [text block]
The following is a summary of changes in the carrying value of intangible assets:
 
   
Product
related
intangibles
    
Customer
related
intangibles
 (2)
  
 
Others
 
 
Total
 
Gross carrying value
                        
Balance as of April 1, 2020   Rs. 87,330       -     Rs. 3,766    
Rs.
 91,096  
Additions
(1)
     6,107       -       304       6,411  
Assets acquired through business combinations
(2)
     14,888       -       -       14,888  
Disposals/De-recognitions     (192 )     -       -       (192 )
Effect of changes in foreign exchange rates     (900 )     -       -       (900 )
Balance as of March 31, 2021
 
Rs.
107,233
 
 
Rs.
-
 
 
Rs.
4,070
 
 
Rs.
111,303
 
                                 
Balance as of April 1, 2021   Rs. 107,233     Rs. -     Rs. 4,070     Rs. 111,303  
Additions     816       -       379       1,195  
Assets acquired through business combinations
(2)
     5       98       3       106  
Disposals/De-recognitions
(3)
     (6,398 )     -       (5 )     (6,403 )
Effect of changes in foreign exchange rates     1,254       -       1       1,255  
Balance as of March 31, 2022
 
Rs.
102,910
 
 
Rs.
98
 
 
Rs.
4,448
 
 
Rs.
107,456
 
Amortization/impairment loss
                                
Balance as of April 1, 2020   Rs. 61,531     Rs. -     Rs. 1,906     Rs. 63,437  
Amortization for the year     3,972       -       297       4,269  
Impairment loss     8,542       -       -       8,542  
Disposals/De-recognitions     (192 )     -       -       (192 )
Effect of changes in foreign exchange rates     (401 )     -       -       (401 )
Balance as of March 31, 2021
 
Rs.
73,452
 
 
Rs.
-
 
 
Rs.
2,203
 
 
Rs.
75,655
 
                                 
Balance as of April 1, 2021   Rs. 73,452     Rs. -     Rs. 2,203     Rs. 75,655  
Amortization for the year     3,415       -       257       3,672  
Impairment loss     4,511       -       -       4,511  
Disposals/De-recognitions
(3)
     (4,519 )     -       (2 )     (4,521 )
Effect of changes in foreign exchange rates     892       -       1       893  
Balance as of March 31, 2022
 
Rs.
77,751
 
 
Rs.
-
 
 
Rs.
2,459
 
 
Rs.
80,210
 
                                 
Net carrying value
                                
As of April 1, 2020   Rs. 25,799     Rs. -     Rs. 1,860     Rs. 27,659  
As of March 31, 2021   Rs. 33,781     Rs. -     Rs. 1,867     Rs. 35,648  
As of March 31, 2022
 
Rs.
25,159
 
 
Rs.
98
 
 
Rs.
1,989
 
 
Rs.
27,246
 
 
(1)
During the year ended March 31, 2021 the Company entered into a definitive agreement with Glenmark Pharmaceuticals Limited to acquire marketing authorizations and other rights of select brands in four “Emerging Markets” countries. The acquired brands represent two products, (a) a mometasone mono product and (b) a combination of mometasone with azelastine, and are indicated for the treatment of seasonal and perennial allergic rhinitis. The total consideration paid was Rs.1,516. Following the principles of IAS 38, the Company recognized the acquired brands at their acquisition cost. The acquisition pertains to the Company’s Global Generics segment.
 
(2)
Refer to Note 6 of these consolidated financial statements for further details.
 
(3)
Disposals/de-recognitions for the year ended March 31, 2022 primarily include the following IPR&D assets:
 
·
Rs.4,498 upon its settlement with Hatchtech Pty Limited regarding their civil litigation and arbitration, relating to the acquisition of the product Xeglyze®. Refer to Note 3
2
(Contingencies) of these consolidated financial statements under “Civil Litigation and Arbitration with Hatchtech Pty Limited” for further details.
·
Rs. 1,879 upon sale of all rights relating to anti-cancer agent E7777 (denileukin diftitox) to Citius Pharmaceuticals, Inc. (“Citius”).
Disclosure Of Detailed Information About Intangible Assets Under Development [Text Block]
Tabulated below is the reconciliation of amounts relating to in-process research and development assets as at the beginning and at the end of the year:
 
 
 
As of March 31,
 
 
 
2022
 
 
2021
 
Opening balance   Rs. 6,113     Rs. 10,987  
Add
: Additions during the year
(1)
     153       3,557  
Less
: Disposals/De-recognitions
(2)
     (1,879 )     -  
Less: Impairments during the year
     (4,435 )     (8,099 )
Effect of changes in exchange rates     186       (332 )
Closing balance
 
Rs.
138
 
 
Rs.
6,113
 

(1)
Additions during the year ended March 31, 2021 include Rs.3,291, representing the expenditure for purchase of intellectual property rights relating to
 
Xeglyze®
forming part of the Company’s Proprietary Products segment.
 
(2)
During the year ended March 31, 2022, the Company entered into a definitive agreement with Citius Pharmaceuticals, Inc. (“Citius”) for the sale of all of its rights relating to its anti-cancer agent E7777 (denileukin diftitox) to Citius. The Company received Rs.2,951 (U.S.$40) as an upfront amount upon the closing of the transaction. Consequent to this definite agreement, the company de-recognised Rs. 1,879 representing the carrying cost of the said asset.  Refer to Note 23 for the amount of gain on sale of such intangible asset.   
 
Description of significant separately acquired Intangible Assets [text block]
Details of significant separately acquired intangible assets as of March 31, 2022 are as follows:
 
Particulars of the asset
  
Acquired from
  
Carrying cost
Select portfolio of branded generics business  
Wockhardt Limited
 
Rs.13,440
Select portfolio of dermatology, respiratory and pediatric assets  
UCB India Private Limited and affiliates
  
4,064
Various ANDAs  
Teva and an affiliate of Allergan
  
3,327
Select Anti-Allergy brands  
Glenmark Pharmaceuticals Limited
  
1,386
Habitrol® brand  
Novartis Consumer Health Inc.
  
1,053